Dasatinib (hydrochloride)

Dasatinib (hydrochloride)

• CAS Number: 854001-07-3
• UNSPSC Description: Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of [1]. Dasatinib hydrochloride also induces apoptosis and autophagy.
• Target Antigen: Apoptosis; Autophagy; Bcr-Abl; Src
• Type: Reference compound
• Related Pathways: Apoptosis;Autophagy;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Dasatinib-hydrochloride.html
• Purity: 99.67
• Solubility: DMSO : 15 mg/mL (ultrasonic;warming)|H2O : 10 mg/mL (ultrasonic)
• Smiles: O=C(C1=CN=C(S1)NC2=NC(C)=NC(N3CCN(CC3)CCO)=C2)NC4=C(C=CC=C4Cl)C.[H]Cl
• Molecular Weight: 524.47
• References & Citations: [1]Lombardo LJ, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 Dec 30;47(27):6658-61.Front Pharmacol. 2023 Aug 29;14:1250383.|J Hematol Oncol. 2018 Aug 29;11(1):109. |PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. |ACS Omega. October 26, 2022.|ACS Pharmacol Transl Sci. 2023 May 2.|Acta Pharmacol Sin. 2024 Jul 23.|Adv Funct Mater. 27 January 2022.|Aging. 2020 Jun 25;12(12):11337-11348.|Artif Cells Nanomed Biotechnol. 2023 Oct 5.|Behav Brain Res. 2022 Dec 16;114260.|Biochem Pharmacol. 2023 Jan 30.|Bioconjug Chem. 2023 Jul 17.|Biogerontology. 2022 Apr 25:1-15.|Biol Pharm Bull. 2017;40(10):1747-1753. |Biomaterials. 16 September 2022.|Biomed Chromatogr. 2019 Dec;33(12):e4674.|Biomed Pharmacother. 2023 Apr 12;162:114680.|Biomed Pharmacother. 2024 Jan 9:171:116124.|Biomolecules. 2022 Jun 11;12(6):819.|bioRxiv. 2023 Dec 14.|bioRxiv. 2024 Jul 30:2024.07.29.605645.|bioRxiv. 2024 July 19.|bioRxiv. 2024 Oct 23:2024.10.20.619300.|Br J Cancer. 2022 Nov 1.|Br J Pharmacol. 2024 Aug 8.|Breast Cancer Res Treat. 2020 Jan;179(2):337-347.|Cancer Cell Int. 2021 Jun 5;21(1):291.|Cancer Cell Int. 2023 Dec 16;23(1):323.|Cancers (Basel). 2022 Mar 11;14(6):1451.|Cell Biochem Funct. 2020 Jul;38(5):642-650.|Cell Commun Signal. 2024 Feb 12;22(1):115.|Cell Death Dis. 2021 Dec 3;12(12):1126.|Cell Mol Gastroenterol Hepatol. 2022 Apr 2;14(1):75-99.|Cell Signal. 2024 Oct.|Cell. 2021 Oct 28;184(22):5670-5685.e23.|Cells. 2023 Dec 14, 12(24), 2836.|Chem Biol Interact. 2021 Oct 27;109729.|Chem Pharm Bull (Tokyo). 2017 Aug 1;65(8):768-775.|Clin Sci. 2021 Jul 20;CS20210571.|Diseases. 2023 Oct 23;11(4):147.|Drug Des Devel Ther. 2024 Sep 12:18:4065-4088.|Eur J Pharmacol. 2021 Feb 10;173944.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Exp Eye Res. 2022 Aug 2;223:109207.|FASEB J. 2024 Jan;38(1):e23355.|FEBS J. 2024 Oct 20.|Front Cell Dev Biol. 2021 Mar 16;9:618045.|Front Microbiol. 2019 Aug 7;10:1816.|Front Pharmacol. 2021 Mar 8;12:644342.|Harvard Medical School LINCS LIBRARY|Hum Exp Toxicol. 2023 Jan-Dec;42:9603271231188492.|Immunity. 2024 Mar 12;57(3):513-527.e6.|Int J Rheum Dis. 2023 Feb 21.|iScience. 2023 Jul 21.|J Anim Sci Biotechnol. 2021 May 10;12(1):63.|J Cancer Res Clin Oncol. 2022 Nov 19.|J Chem Inf Model. 2024 Jun 7.|J Clin Invest. 2019 Mar 1;129(3):972-987.|J Clin Invest. 2023 Feb 16;e162324.|J Hematol Oncol. 2022 Apr 29;15(1):46.|J Hematol Oncol. 2024 Dec 18;17(1):122.|J Immunol Res. 2022 Apr 28;2022:6324326.|J Immunother Cancer. 2020 Mar;8(1):e000111. |J Med Chem. 2021 Mar 11;64(5):2725-2738.|J Med Chem. 2021 Sep 21.|J Med Chem. 2024 Nov 28;67(22):20571-20579.|J Pharm Anal. 2021 Jun 19.|J Pineal Res. 2019 Sep;67(2):e12588. |J Toxicol Sci. 2024;49(8):337-348.|J Transl Med. 2022 Jun 21;20(1):278.|J Virol. 2024 Sep 17:e0112924.|Kawasaki Medical Journal. 43(2)：63-78，2017.|Leukemia. 2012 Oct;26(10):2233-44.|Leukemia. 2020 Jun;34(6):1524-1539. |Matrix Biol. 2024 Mar:127:48-56.|Med Oncol. 2022 Dec 16;40(1):49.|Mol Ther. 2023 Feb 28;S1525-0016(23)00116-8.|Molecules. 2018 Mar 23;23(4). pii: E736.|Nat Aging. 2024 Apr;4(4):527-545.|Nat Biomed Eng. 2018 Aug;2(8):578-588.|Nat Cell Biol. 2023 Mar;25(3):493-507.|Nat Commun. 2020 Apr 14;11(1):1790.|Nat Commun. 2020 Apr 20;11(1):1913. |Oncogenesis. 2022 Apr 11;11(1):15.|Oncotarget. 2016 Aug 30;7(35):56241-56252. |Patent. US10174018B2.|Patent. US20180099959A1.|Patent. US20180099960A1.|Patent. US20180099961A1.|Patent. US20180263995A1.|Patent. US20230226111A1.|Patent. US20240238271A1.|Patent. US20240325538A1.|PLoS One. 2013;8(2):e56473.|PLoS One. 2018 Jun 14;13(6):e0199208.|Purdue University. Department of Chemistry.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|SSRN. 2024 Apr 1.|Stem Cell Reports. 2017 Dec 12;9(6):1948-1960.|Target Oncol. 2020 Oct;15(5):659-671.|Technical University of Munich. 24.01.2018.|University of Düsseldorf. 2024.|Int J Pharm Res Allied Sci. 2023 Mar;13(1):139-148.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, stored under nitrogen)
• Clinical Information: Launched